Fosamax Formulary Analysis: Health Plans Shift Tiers Or Delete Brand
Executive Summary
A number of major health insurers are in the process of moving Merck's Fosamax (alendronate) to higher cost-sharing tiers or off formularies altogether following the recent launch of generic competitors